Showing results (61-70 of 84) with videos related to

Sort By:
Pageof 9
The Oncologist|June 2, 2019
Characteristics of BRAF Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 PatientsChristelle de la Fouchardière, Romain Cohen, David Malka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2025
Acquired high tumor mutational burden and activity of immunotherapy after targeted therapy in microsatellite stable colorectal cancerCeline Yeh, Oliver Artz, Haochen Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2024
Analysis of Shared Variants between Cancer BiospecimensMichael B Foote, James Robert White, Walid K Chatila, et al.
Cancer Cell|June 13, 2025
Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer modelsPietro Paolo Vitiello, Benoit Rousseau, Rosaria Chilà, et al.
Hepatology (Baltimore, Md.)|November 21, 2017
New insights into diagnosis and therapeutic options for proliferative hepatoblastomaKatarzyna B Hooks, Jérôme Audoux, Helena Fazli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2022
Molecular Classification of Appendiceal AdenocarcinomaMichael B Foote, Henry Walch, Walid Chatila, et al.
Oncogene|March 24, 2022
Discoidin Domain Receptor 2 orchestrates melanoma resistance combining phenotype switching and proliferationMargaux Sala, Nathalie Allain, Mélanie Moreau, et al.
Medrxiv : the Preprint Server for Health Sciences|July 3, 2026
Emergency integrative supportive care program for frail patients with advanced pancreatic cancer: A prospective GERCOR ARCAD studyBenoit Rousseau, Marc Hilmi, Antoine Falcoz, et al.
Cancer Medicine|June 15, 2019
NF1 mutations identify molecular and clinical subtypes of lung adenocarcinomasCamille Tlemsani, Nicolas Pécuchet, Aurelia Gruber, et al.
Oncotarget|December 20, 2017
Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO studyJuliette Palle, David Tougeron, Astrid Pozet, et al.
Pageof 9